Episode 1: Are We Ready for Biology Driven Bladder Cancer Care

In this inaugural episode, Dr. Nitin Yerram is joined by Dr. Saum Ghodoussipour for a wide‑ranging discussion on whether bladder cancer care is finally ready to move beyond traditional pathology and toward biology‑driven, precision medicine. Together, they unpack what precision medicine truly means in bladder cancer, why a one‑size‑fits‑all treatment paradigm leads to both overtreatment and undertreatment, and how advances in molecular subtyping and genomics are reshaping how clinicians think about risk, response, and cure. The conversation focuses on muscle‑invasive bladder cancer (MIBC), exploring luminal versus non‑luminal molecular subtypes, the role of commercially available tools like Decipher Bladder, and how tumor biology may influence responsiveness to neoadjuvant chemotherapy and immunotherapy. Drs. Yerram and Ghodoussipour discuss ongoing clinical trials, including initiatives aimed at safely de‑escalating therapy in select patients, while emphasizing the importance of survival, toxicity, and patient‑reported outcomes. The episode closes with a forward‑looking vision of multiomic, AI‑enabled precision care, and a reminder that truly personalized treatment begins with understanding the patient, not just the biopsy.